Title: Scientific Director of Precision Medicine
Company: Riley Hospital for Children
Location: Indianapolis, Indiana, United States
Mark S. Marshall, PhD, scientific director of precision medicine at Riley Hospital for Children, has been recognized by Marquis Who’s Who Top Scientists for dedication, achievements, and leadership in cancer research and drug development.
With nearly three and a half decades of experience, Dr. Marshall has built a successful career in health care, focusing on drug development and cancer research. He has served as the scientific director of precision medicine at Riley Hospital for Children since 2016 and as an adjunct professor at Indiana University School of Medicine since 1999. His responsibilities include consulting with oncologists on pediatric patients with high-risk or relapsed cancer, performing DNA sequencing of tumors to identify underlying genetic causes, and reviewing genomic data to detect mutations critical for diagnosis. His experience also includes research fellow at Lilly Research Laboratories from 2004 to 2015, leader of the Protein Kinase Discovery Platform at Lilly Research Laboratories from 2001 to 2005, and research advisor in cancer research at Lilly Research Laboratories from 1999 to 2004. He was a professor at Indiana University School of Medicine from 1998 to 1999 and served as associate scientific director at the Walther Oncology Center during the same period. He was an associate professor at Indiana University School of Medicine from 1991 to 1998, a senior research biochemist at Merck Sharp & Dohme Research Laboratories from 1988 to 1991, and a post-doctoral research scientist at the same institution from 1985 to 1987.
Dr. Marshall has contributed to professional journals with articles such as “1989 PDGF induces rapid tyrosine phosphorylation of the Ras p21GTPase activating protein (GAP) in quiescent NIH3T3 fibroblasts,” “A C-Terminal domain of GAP is sufficient to stimulate ras p21 GTPase activity,” and “A Novel Role of p38a MAPK in Mitotic Progression Independent of Its Kinase Activity.” He also dedicates his time as vice-chairman of the Biochemistry and Endocrinology Study Section and is a member of the American Cancer Society and the Institute of Molecular and Cellular Biology. He served as a scout leader for the Boy Scouts of America from 1995 to 2011 and has volunteered at a local children’s museum and local church. Throughout his career, he has also developed patents for “Amino pyrazoles as Chk1 Inhibitors” and “Preparation of Amino pyrazole compound useful for inhibiting Chk1,” both granted in 2011. Laying a solid educational foundation for these successes, he earned a Bachelor of Science in microbiology from Brigham Young University in 1980, a Master of Science in microbiology from Brigham Young University in 1982, and a PhD in molecular biology from Princeton University in 1986.
Reflecting on his path, Dr. Marshall has achieved success in leading drug development teams, with several of the drugs developed under his leadership currently undergoing clinical trials. While pursuing a master’s degree in the early eighties, he developed a vaccine called M9 Dax to combat cholera in turkeys and chickens. This vaccine remains in use today and has likely contributed to addressing world hunger, particularly in regions where turkey and chicken are staple foods. He attributes success to his unwavering determination, faith, and the support of his family and colleagues. In the coming years, his goal is to focus on his well-being and spend quality time with his family. He prioritizes his health and cherishes experiences with loved ones, aiming to shift his focus from volunteer work and career to nurturing personal aspects of his life. He has also considered seeking a consultancy role to ensure a balanced and fulfilling future.
For more information, please visit:
Contact Dr. Marshall:
